ATE538809T1 - Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff - Google Patents

Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff

Info

Publication number
ATE538809T1
ATE538809T1 AT04746847T AT04746847T ATE538809T1 AT E538809 T1 ATE538809 T1 AT E538809T1 AT 04746847 T AT04746847 T AT 04746847T AT 04746847 T AT04746847 T AT 04746847T AT E538809 T1 ATE538809 T1 AT E538809T1
Authority
AT
Austria
Prior art keywords
vaccine
selecting appropriate
biological sample
precursor cells
highly responsive
Prior art date
Application number
AT04746847T
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE538809T1 publication Critical patent/ATE538809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
AT04746847T 2003-06-27 2004-06-25 Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff ATE538809T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003184436 2003-06-27
JP2004070497 2004-03-12
PCT/JP2004/009378 WO2005001117A1 (ja) 2003-06-27 2004-06-25 Ｗｔ１ワクチン適応患者の選択方法

Publications (1)

Publication Number Publication Date
ATE538809T1 true ATE538809T1 (de) 2012-01-15

Family

ID=33554467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04746847T ATE538809T1 (de) 2003-06-27 2004-06-25 Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff

Country Status (9)

Country Link
US (1) US10500257B2 (de)
EP (3) EP2338509B1 (de)
JP (1) JP4566912B2 (de)
KR (2) KR101292971B1 (de)
CN (1) CN1842603B (de)
AT (1) ATE538809T1 (de)
CA (2) CA2530184C (de)
ES (3) ES2478446T3 (de)
WO (1) WO2005001117A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
CN1281625C (zh) 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
EP1550453B1 (de) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Präparat eines peptids eines krebs-antigens
ES2478446T3 (es) 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
WO2005045027A1 (ja) 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
PT1731605E (pt) * 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
DK1853305T3 (en) * 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
EP2565201B1 (de) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1-HLA-Klasse II-bindende Peptide und Zusammensetzungen und Verfahren damit
SI1961761T1 (sl) * 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
EP2010209B1 (de) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verfahren zu ihrer verwendung
ES2539042T3 (es) * 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
MX352947B (es) 2007-02-27 2017-12-14 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
WO2009072610A1 (ja) 2007-12-05 2009-06-11 International Institute Of Cancer Immunology, Inc. 癌ワクチン組成物
SG189287A1 (en) 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
EP2561759A1 (de) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoralkyl-substituierte 2-amidobenzimidazole und ihre Wirkung auf das Pflanzenwachstum
CN107897194A (zh) 2011-09-16 2018-04-13 拜耳知识产权有限责任公司 5‑苯基‑或5‑苄基‑2‑异噁唑啉‑3‑甲酸酯用于改善植物产量的用途
CN103781352A (zh) 2011-09-16 2014-05-07 拜耳知识产权有限责任公司 苯基吡唑啉-3-甲酸酯类用于提高植物产量的用途
BR112014006217B1 (pt) 2011-09-16 2019-01-15 Bayer Intellectual Property Gmbh utilização de acilsulfonamidas para melhorar o rendimento de plantas,método para induzir respostas de regulação de crescimento em plantas úteis ou plantas de cultura e composição.
EP3520810A3 (de) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogene wt-1-peptide und verwendung davon
JP6273290B2 (ja) 2012-10-23 2018-01-31 ユビバック エルエルシー 疾患の処置のための同種異系のオートファゴソーム強化組成物
AR094026A1 (es) 2012-12-17 2015-07-08 Otsuka Pharma Co Ltd Metodo para activar la celula t helper
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
LT2945647T (lt) * 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US9963431B2 (en) 2013-03-05 2018-05-08 Bayer Cropscience Ag Use of quinoline derivatives for improving plant yield
CN105307493A (zh) 2013-03-05 2016-02-03 拜耳作物科学股份公司 酰基磺酰胺用于提高植物产量的用途
CA2908117A1 (en) * 2013-03-28 2014-10-02 Centre Hospitalier Universitaire De Montpellier Method for determining radiosensitivity
WO2014185387A1 (ja) * 2013-05-13 2014-11-20 株式会社癌免疫研究所 免疫療法の臨床効果の予測法
HUE059694T2 (hu) 2015-11-20 2022-12-28 Memorial Sloan Kettering Cancer Center Készítmény rák kezelésére
EP3318135A1 (de) 2016-11-03 2018-05-09 Perfetti Van Melle S.p.A. Sprudelndes süssigkeitenmaterial, verfahren zu dessen herstellung und daraus hergestellte produkte
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
TWI875736B (zh) * 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
KR20230009426A (ko) * 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
JP7835418B1 (ja) * 2025-01-14 2026-03-25 国立大学法人神戸大学 がんワクチンの効果予測

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
EP0602178A4 (en) 1991-08-28 1995-10-25 Wistar Inst T cell receptor-based therapy for rheumatoid arthritis.
US5364787A (en) 1992-03-23 1994-11-15 Idaho Research Foundation Genes and enzymes involved in the microbial degradation of pentachlorophenol
DE69733629T2 (de) * 1996-04-16 2006-05-18 Kishimoto, Tadamitsu, Tondabayashi Verfahren zum nachweis solider krebszellen und histologischer heterotypien und verfahren zur prüfung von gewebe für die knochenmarktransplantation und die transplantation von peripheren blutstammzellen
GB9710820D0 (en) 1997-05-27 1997-07-23 Univ Dundee Immunological method
US6013444A (en) 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
KR100752065B1 (ko) 1998-09-30 2007-08-28 코릭사 코포레이션 Ｗｔ1 특이적 면역요법용 조성물 및 방법
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
CA2362099C (en) 1999-02-23 2014-05-13 Baylor College Of Medicine T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection
CA2410510A1 (en) * 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用
CN1281625C (zh) 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
WO2003002142A1 (fr) 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Vaccin anticarcinogene contenant un antigene tumoral base sur un produit de gene wt1 suppresseur de tumeur et des liposomes cationiques
US20060035291A1 (en) 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
EP1447092A4 (de) 2001-09-28 2007-07-11 Haruo Sugiyama Neues verfahren zur induktion von antigenspezifischen t-zellen
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
AU2003207528A1 (en) 2002-01-09 2003-07-30 Maxx Genetech Co. Ltd Method of detecting t-cell proliferation for diagnosis of diseases by gene array
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
EP1550453B1 (de) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Präparat eines peptids eines krebs-antigens
WO2004063706A2 (en) 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Method of detecting over-expression of t-cell receptor genes by real-time pcr
ES2478446T3 (es) 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
WO2005045027A1 (ja) 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2005053603A2 (en) 2003-12-08 2005-06-16 Yeda Research And Development Co. Ltd. Antigen receptor variable region typing
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay
WO2008026927A2 (en) 2006-08-30 2008-03-06 Academisch Medisch Centrum Process for displaying t- and b-cell receptor repertoires
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
JP2009278927A (ja) 2008-05-23 2009-12-03 Tohoku Univ Ｔ細胞受容体を模倣する抗体断片及びその製造方法
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell

Also Published As

Publication number Publication date
US10500257B2 (en) 2019-12-10
CN1842603A (zh) 2006-10-04
EP1640458A4 (de) 2008-05-21
EP2338509A3 (de) 2011-11-30
CA2530184C (en) 2015-10-06
ES2378156T3 (es) 2012-04-09
WO2005001117A1 (ja) 2005-01-06
CN1842603B (zh) 2013-09-11
CA2530184A1 (en) 2005-01-06
EP1640458B1 (de) 2011-12-28
JPWO2005001117A1 (ja) 2006-08-10
ES2443582T3 (es) 2014-02-19
HK1090093A1 (en) 2006-12-15
CA2893995A1 (en) 2005-01-06
JP4566912B2 (ja) 2010-10-20
KR20060069363A (ko) 2006-06-21
KR20110049877A (ko) 2011-05-12
US20070128207A1 (en) 2007-06-07
KR101292971B1 (ko) 2013-08-12
EP2343083A2 (de) 2011-07-13
EP2343083A3 (de) 2011-08-03
EP1640458A1 (de) 2006-03-29
EP2338509A2 (de) 2011-06-29
KR101431312B1 (ko) 2014-08-20
EP2343083B1 (de) 2014-01-15
ES2478446T3 (es) 2014-07-22
EP2338509B1 (de) 2014-06-18

Similar Documents

Publication Publication Date Title
EP1640458A4 (de) Verfahren zur auswahl von für den wt1-impfstoff geeigneten patienten
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE399323T1 (de) Verfahren zur bestimmung von amyloidogenen proteinen
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
RU2007141067A (ru) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
DE602005020956D1 (de) Verfahren und gerät zur identifikation von lebendigen eiern mittels pulsfrequenz und embryobewegung
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
Lu et al. Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS
JP5866053B1 (ja) 皮膚粘弾性のマーカー及びその利用
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
EA201170365A1 (ru) Способ и устройство диагностики и скрининга заболеваний с использованием электромагнитных полей сверхнизкой частоты
ATE184703T1 (de) Verfahren und testsatz zur messung von endogenen zytokinen
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
ATE520987T1 (de) Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
DE60025170D1 (de) Diagnostisches verfahren für asthma
EP1476757A4 (de) Verfahren und kit zur krebsvorhersage
DE602006015727D1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
DE10391021D2 (de) Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens